Lilan Ling

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index9.8kcitations62works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gut microbiota and health(32), Clostridium difficile and Clostridium perfringens research(18), Helicobacter pylori-related gastroenterology studies(11), Gastric Cancer Management and Outcomes(7), Cancer, Stress, Anesthesia, and Immune Response(7)

Publications62 total

Active learning guides automated discovery of DNA delivery via electroporation for non-model microbes
2025Open Access
Figure S1, Panel B from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S3 from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Supplementary Figure Legends from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Data from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S1, Panel A from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S1, Panel B from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S3 from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Data from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Supplementary Figure Legends from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S2 from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S1, Panel A from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S1, Panel C and D from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S1, Panel C and D from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Figure S2 from Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden
2023Open Access
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Nature Communications·2022· 53 citedOpen Access
Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.
Journal of Clinical Oncology·2021· 2 cited
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs
JCO Precision Oncology·2020· 17 citedOpen Access
Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis.
Journal of Clinical Oncology·2020· 6 cited
Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection
Nature Communications·2019· 227 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Eric G. Pamer(40), Ying Taur(18), Eric R. Littmann(13), Marcel R.M. van den Brink(13), Robert R. Jenq(10), Jonathan U. Peled(9), Ingrid M. Leiner(9), David C. Montrose(8), Xi Kathy Zhou(8), Erin M. McNally(8), Erika Sue(8), Steven S. Gross(8), Nitai D. Leve(8), Edward D. Karoly(8), Andrew J. Dannenberg(8), Asia Gobourne(7), Miguel‐Angel Perales(7), Juliet N. Barker(7), Sergio Giralt(7), Liza Miller(7)